Please login to the form below

Not currently logged in

Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial

Results showing that the drug is an improvement on Xalkori were released at ESMO 2020 virtual congress

Pfizer’s Lorbrena has come out on top in a head-to-head trial against its older ALK inhibitor Xalkori in previously untreated non-small cell lung cancer (NSCLC) with this specific genetic mutation.

Lorbrena (lorlatinib) reduced the risk of disease progression or death by 72% in ALK-positive NSCLC patients compared to Xalkori (crizotinib) in the phase 3 CROWN trial, presented over the weekend at the 2020 European Society for Medical Oncology (ESMO) virtual congress.

In the same trial, the progression-free survival rate was not yet estimable for Lorbrena, compared to 9.3 months for Xalkori. The intracranial objective response rate was 82% in patients with measurable brain metastases, with a complete response rate of 71% associated with Lorbrena treatment.

Despite the NSCLC market being largely dominated by Merck & Co/MSD’s Keytruda (pembrolizumab), the ALK-positive patient group is an important subset, with this type of tumour mutation occurring in around 3-5% of all cases.

Follow-up ALK inhibitors are particularly crucial in this treatment setting, given that many patients experience tumour progression after initial treatment and often require a second- or third-line option. It is also important to note that central nervous system progression often occurs in this type of cancer, wherein the cancer spreads to the brain.

“These results of the CROWN study support the use of Lorbrena as a highly effective first-line therapy for patients with advanced ALK-positive non–small cell lung cancer,” said lead study author Ben Solomon, a medical oncologist in the Lung Service and the Head and Neck service.

The company added that it also intends to share the results from the study with the US Food and Drug Administration (FDA) and other health regulators across the globe to support its approval ambitions.

Currently, Lorbrena is approved only in the second-line setting, for patients who have already been treated with one or more therapies, including Xalkori and treatments from other competitors.

Article by
Lucy Parsons

21st September 2020

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Havas Life Medicom

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....